An observational study in Fibrous Dysplasia, Fibrous Dysplasia of Bone and Fibrous Dysplasia/McCune-Albright Syndrome, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Istituto Ortopedico Rizzoli · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Fibrous dysplasia is a benign, pseudotumoral, genetic but non-hereditary condition characterized by the presence of one or more areas of abnormal bone development in which the normal structure is replaced by fibrous tissue. It is an extremely heterogeneous condition, as it can be monostotic, polyostotic, or panostotic, or it may occur within the context of more complex syndromes such as McCune-Albright syndrome (in which polyostotic fibrous dysplasia is associated with café-au-lait spots and precocious puberty) or Mazabraud syndrome (in which intramuscular myxomas are present).
This condition is caused by post-zygotic missense mutations, so it is never hereditary, and the affected individual will constitute a so-called "genetic mosaic," a fact that explains the wide variability in the localization of the pathological areas. The mutations in question occur in a gene (GNAS) located on chromosome 20 (20q13.2-13.3); this gene encodes a G protein with GTPase activity, the function of which is consequently impaired.
The aim of this study is to evaluate in detail the characteristics of the patients, their hospitalizations, and related interventions. Given the rarity of the condition, such investigations are often conducted on very limited datasets. The present study is expected to include over 200 patients, providing a comprehensive picture.
An additional aim is to assess the impact of somatic mutations in the GNAS gene and their impact in terms of clinical manifestations.
23 studies on the registry are indexed under Fibrous Dysplasia, Polyostotic; 5 are open to participants now.
Browse Fibrous Dysplasia, Polyostotic studies →Istituto Ortopedico Rizzoli is the lead sponsor of 305 studies on the registry; 104 are open to participants now.
Compared within Fibrous Dysplasia, Polyostotic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrous Dysplasia of Bone. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All consecutive patients affected by Fibrous Dysplasia, McCune-Albright syndrome and Mazabraud syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients affected by Fibrous Dysplasia, McCune-Albright syndorme and Mazabraud syndrome with available clinical, radiological and surgical data
All patients affected by Fibrous Dysplasia, McCune-Albright syndorme and Mazabraud syndrome with an available tissue biospecimens for molecular investigation
Description of surgical procedures
Analyze the correlation between the reason for hospitalization (e.g. pain, fractures, etc.), the resulting type of procedure (categorized surgical procedures), and the patients' characteristics considering age (years), sex (male or female), lesion dimension (in cm).
Time frame: 4 years
Description of clinical features of Fibrous Dysplasia patients
Describe natural history of patients affected by Fibrous Dysplasia, McCune-Albright syndorme and Mazabraud syndrome
Time frame: 4 years
Genotype-phenotype correlation
Identification of somatic pathogenic variants (described using HGMD) and genotype-phenotype correlation of molecular data with available clinical information
Time frame: 4 years
Number and types of post-interventions complications and pain
To analyze the number and types of complications following surgeries (e.g. additional surgery, functional limitations) for fibrous dysplasia and to assess the impact of surgery on long bones in terms of pain (presence/absence)
Time frame: 4 years
Plan to share: No — The data are not publicly available due to privacy and/or ethical restrictions
Started May 2022 (actual). Primary completion is estimated for Jan 2027, 56 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2026 → Jan 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fibrous Dysplasia, Polyostotic →